Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Thumbnail
View
Author
Rejeski, Kai ORCID
Villacampa Javierre, Guillermo ORCID
van Doesum, Jaap ORCID
CHIAPPELLA, ANNALISA ORCID
Bonifazi, Francesca ORCID
Marin Niebla, Ana ORCID
Barba, Pere ORCID
IACOBONI, GLORIA ORCID
Camacho-Arteaga, Lina ORCID
Date
2022-06-28
Permanent link
https://hdl.handle.net/11351/9613
DOI
10.1182/bloodadvances.2021006922
ISSN
2473-9529
WOS
000836434600006
PMID
35271707
Share on TwitterShare on FacebookShare on TelegramShare on WhatsappShare on Linkedin

Show full item record
Keywords
Treatment; Mantle cell lymphoma; Relapsed
Bibliographic citation
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606–10.
Audience
Professionals
This item appears in following collections

The following license files are associated with this item: